Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares

Zealand Pharma's Annual General Meeting 2023

Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396

Zealand Pharma Provides Update on Silicon Valley Bank Closure

Zealand Pharma Provides Statement on Silicon Valley Bank Closure

Zealand Pharma A/S (ZEAL) Q4 2022 Results Conference Call March 1, 2022 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO Henriette Wennicke - CFO David Kendall - CMO Conference Call Participants Thomas Bowers - Danske Bank Brian Balchin - Jefferies Michael Novod - Nordea Jesper Ilsoe - Carnegie Mark Purcell - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Zealand Pharma Results for the Full Year 2022 Conference Call.

Zealand Pharma A/S (ZEAL) Q4 2022 Earnings Call Transcript

Correction: Zealand Pharma Announces Full Year Results for 2022

Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company").

Zealand Pharma convenes its Annual General Meeting 2023

Zealand Pharma Announces Full Year Results for 2022

Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022

Zealand Pharma grants sign-on warrants and performance stock units under the employee warrant program and management long-term incentive program

Zealand Pharma A/S (ZEAL) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Anna Krassowska - Vice President, Investor Relations & Corporate Communications Adam Steensberg - President & Chief Executive Officer Henriette Wennicke - Chief Financial Officer David Kendall - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Company Brian Balchin - Jefferies Operator Good day and thank you for standing by. Welcome to Zealand Pharma Results for Third Quarter 2022 Conference Call.

Zealand Pharma A/S (ZEAL) Q3 2022 Earnings Call Transcript

Zealand Pharma Announces Financial Results for the First Nine Months of 2022

Zealand Pharma to Participate in Upcoming Investor Conferences

Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022

Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting

Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million

Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

Zealand Pharma grants warrants to employees in Denmark

Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)

Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer

News for Zealand Pharma Stock (ZEAL)